Premas Biotech

Premas is developing transformational technologies and partnering with pharmaceutical companies around the world to expedite their drug discovery programs by cutting down significantly both on costs & time to clinics. Axtex-4D, a three-dimensional cell culture platform, engineered to produce high-throughput screens for targeted immuno-oncology drug candidates, is compelling scientists to relook at their tumor-targeting strategies. The ex-vivo culture systematically mirrors the in-vivo tumor microenvironment and is poised to revolutionize both drug discovery & combinatorial therapies. D-Crypt, a platform for 'difficult-to-express’ proteins, is designed to considerably reduce time, cost, and risks associated with producing high-quality recombinant proteins. D-Crypt combines a yeast expression host with over 20 custom-made expression vectors. C-Qwence, our naive India-based Antibody Library is harnessing the power of a genetic pool that is more diverse than any other region and has exposures to infectious diseases and changes in an environment not seen in Europe or America. C-Qwence captures a wealth of novel genetics and protective immune responses, demonstrated in the unique profiles of individual antibodies isolated from the libraries. Combining our breakthrough technologies with state-of-the-art Gene to IND biologics development capabilities, Premas is seeking new partnerships with pharmaceutical companies to help accelerate the delivery of new medicines to patients.